$RGLS
Regulus Therapeutics Inc.

2024 Q4 Form 10-Q Financial Statement

#000162828024046316 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.863M
YoY Change 46.49%
% of Gross Profit
Research & Development $11.35M
YoY Change 106.76%
% of Gross Profit
Depreciation & Amortization $90.00K
YoY Change 76.47%
% of Gross Profit
Operating Expenses $15.21M
YoY Change 87.2%
Operating Profit -$15.21M
YoY Change 87.2%
Interest Expense $1.148M
YoY Change 737.96%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$14.06M
YoY Change 79.73%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$14.06M
YoY Change 79.73%
Net Earnings / Revenue
Basic Earnings Per Share -$0.21
Diluted Earnings Per Share -$0.21
COMMON SHARES
Basic Shares Outstanding 65.50M shares 65.47M shares
Diluted Shares Outstanding 65.47M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $87.31M
YoY Change 183.64%
Cash & Equivalents $26.37M
Short-Term Investments $60.94M
Other Short-Term Assets $1.087M
YoY Change -11.48%
Inventory
Prepaid Expenses $3.229M
Receivables
Other Receivables
Total Short-Term Assets $91.69M
YoY Change 161.35%
LONG-TERM ASSETS
Property, Plant & Equipment $1.023M
YoY Change 1.49%
Goodwill
YoY Change
Intangibles $25.00K
YoY Change -30.56%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.076M
YoY Change -22.1%
TOTAL ASSETS
Total Short-Term Assets $91.69M
Total Long-Term Assets $2.076M
Total Assets $93.76M
YoY Change 148.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $792.0K
YoY Change 32.22%
Accrued Expenses $1.107M
YoY Change 78.55%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $6.482M
YoY Change -21.41%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $476.0K
YoY Change -61.61%
Total Long-Term Liabilities $476.0K
YoY Change -61.61%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.482M
Total Long-Term Liabilities $476.0K
Total Liabilities $6.958M
YoY Change -26.67%
SHAREHOLDERS EQUITY
Retained Earnings -$546.8M
YoY Change 8.24%
Common Stock $633.5M
YoY Change 18.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $86.81M
YoY Change
Total Liabilities & Shareholders Equity $93.76M
YoY Change 148.4%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$14.06M
YoY Change 79.73%
Depreciation, Depletion And Amortization $90.00K
YoY Change 76.47%
Cash From Operating Activities -$9.449M
YoY Change 50.63%
INVESTING ACTIVITIES
Capital Expenditures $28.00K
YoY Change -94.83%
Acquisitions
YoY Change
Other Investing Activities $18.67M
YoY Change -481.14%
Cash From Investing Activities $18.64M
YoY Change -442.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 56.00K
YoY Change -80.62%
NET CHANGE
Cash From Operating Activities -9.449M
Cash From Investing Activities 18.64M
Cash From Financing Activities 56.00K
Net Change In Cash 9.251M
YoY Change -180.97%
FREE CASH FLOW
Cash From Operating Activities -$9.449M
Capital Expenditures $28.00K
Free Cash Flow -$9.477M
YoY Change 39.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35670
dei Entity Registrant Name
EntityRegistrantName
Regulus Therapeutics Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4738379
dei Entity Address Address Line1
EntityAddressAddressLine1
4224 Campus Point Court, Suite 210
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
202-6300
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
RGLS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23767000 usd
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
60936000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
0 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
62000 usd
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
62000 usd
dei Amendment Flag
AmendmentFlag
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
65500134 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26373000 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3229000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3010000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1087000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1340000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
91687000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
28179000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1023000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1061000 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
25000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
33000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1028000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1477000 usd
CY2024Q3 us-gaap Assets
Assets
93763000 usd
CY2023Q4 us-gaap Assets
Assets
30750000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
792000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
204000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1107000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
691000 usd
CY2024Q3 rgls Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1366000 usd
CY2023Q4 rgls Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
921000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2453000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2979000 usd
CY2024Q3 us-gaap Debt Current
DebtCurrent
0 usd
CY2023Q4 us-gaap Debt Current
DebtCurrent
1334000 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
764000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2379000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6482000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8508000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
476000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1055000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
6958000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
9563000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7013000 usd
dei Document Type
DocumentType
10-Q
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65500134 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Small Business
EntitySmallBusiness
true
us-gaap Operating Expenses
OperatingExpenses
36294000 usd
us-gaap Operating Expenses
OperatingExpenses
22809000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15210000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8125000 usd
CY2024Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToParent
-45000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8469000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
107588000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.19
dei Entity Central Index Key
EntityCentralIndexKey
0001505512
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65500134 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20222672 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20222672 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
66000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
20000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
633394000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
534375000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
120000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-546780000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-513213000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
86805000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
21187000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
93763000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30750000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11347000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5488000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25695000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15389000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3863000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2637000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10599000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7420000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
15210000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
8125000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-36294000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-22809000 usd
CY2024Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
1153000 usd
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
438000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
2873000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
1324000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
5000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
137000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
145000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
490000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14062000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7824000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33566000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21975000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-14062000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7824000 usd
us-gaap Net Income Loss
NetIncomeLoss
-33567000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21976000 usd
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
207000 usd
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
120000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13855000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7824000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33447000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21976000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.19
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65471132 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65471132 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19628815 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19628815 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53272582 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53272582 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18535209 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18535209 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
21187000 usd
CY2024Q1 rgls Stock Issued During Period Value Stock Issued From Private Placement Net Of Offering Costs
StockIssuedDuringPeriodValueStockIssuedFromPrivatePlacementNetOfOfferingCosts
93897000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
31000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
985000 usd
CY2024Q2 rgls Stock Issued During Period Value Stock Issued From Private Placement Net Of Offering Costs
StockIssuedDuringPeriodValueStockIssuedFromPrivatePlacementNetOfOfferingCosts
-43000 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-152000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1865000 usd
CY2024Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToParent
-42000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11036000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
98181000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
33000 usd
CY2024Q3 rgls Stock Issued During Period Value Stock Issued From Private Placement Net Of Offering Costs
StockIssuedDuringPeriodValueStockIssuedFromPrivatePlacementNetOfOfferingCosts
6000 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2422000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-14062000 usd
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToParent
207000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
86805000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
33291000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
21000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
410000 usd
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToParent
12000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7139000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
26595000 usd
CY2023Q2 rgls Stock Issued During Period Value Stock Issued From Private Placement Net Of Offering Costs
StockIssuedDuringPeriodValueStockIssuedFromPrivatePlacementNetOfOfferingCosts
14003000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
382000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
33997000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1089000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
24000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
973000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7824000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
28259000 usd
us-gaap Net Income Loss
NetIncomeLoss
-33567000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21976000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
260000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
151000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5272000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1765000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-1172000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-107000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
42000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
113000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
219000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
0 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-253000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-619000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
588000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
424000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
542000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-411000 usd
rgls Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
445000 usd
rgls Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
-459000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-526000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-68000 usd
rgls Operating Lease Right Of Use And Lease Liabilities Net Gain Loss
OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss
-81000 usd
rgls Operating Lease Right Of Use And Lease Liabilities Net Gain Loss
OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss
-63000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1665000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-631000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29828000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20643000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
83643000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
4899000 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
24000000 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
15000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
340000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
542000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59983000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9559000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
93860000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
14004000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
-69000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1163000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
1377000 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
2478000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
92417000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12689000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2606000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1605000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23829000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24290000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26435000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25895000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26373000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25833000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
62000 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
62000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26435000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25895000 usd
us-gaap Interest Paid Net
InterestPaidNet
62000 usd
us-gaap Interest Paid Net
InterestPaidNet
375000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000 usd
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
0 usd
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
71000 usd
CY2024Q3 rgls Financingfrom Sale Proceeds Debt Agreement Revenues
FinancingfromSaleProceedsDebtAgreementRevenues
651700000 usd
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
87300000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Use of Estimates</span></div>Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
47142215 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
43627194 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33225055 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25211143 shares
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
60816000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
120000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
60936000 usd
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
85272000 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
23084000 usd
rgls Number Of Amendments
NumberOfAmendments
10 amendment
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65500134 shares
CY2024Q3 rgls Common Stock Voting Rights Votes
CommonStockVotingRightsVotes
1 vote
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14108000 shares
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
61156000 shares
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2422000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
973000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5272000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1765000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
202000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
824000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
277000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1303000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
63000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1240000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
764000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
476000 usd
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001628280-24-046316-index-headers.html Edgar Link pending
0001628280-24-046316-index.html Edgar Link pending
0001628280-24-046316.txt Edgar Link pending
0001628280-24-046316-xbrl.zip Edgar Link pending
ex-311x20240930.htm Edgar Link pending
ex-312x20240930.htm Edgar Link pending
ex-321x20240930.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgls-20240930.htm Edgar Link pending
rgls-20240930.xsd Edgar Link pending
Show.js Edgar Link pending
rgls-20240930_def.xml Edgar Link unprocessable
rgls-20240930_lab.xml Edgar Link unprocessable
rgls-20240930_pre.xml Edgar Link unprocessable
rgls-20240930_htm.xml Edgar Link completed
rgls-20240930_cal.xml Edgar Link unprocessable